A single monoclonal antibody isolated from a human survivor of Ebola virus disease (EVD) completely protected monkeys from lethal infection with the virus, according to research published in today’s online edition of the journal Science. Importantly, the antibody, known as mAb114, was effective even when given five days after exposure to Ebola virus, suggesting that it could hold promise as a potential treatment for human cases of EVD.